Knowledge of Levododopa-induced Dyskinesias among PD patients
Objective: The aim of this study was to investigate the level of knowledge of LIDs in PD patients and their proxies in a tertiary hospital. …Impact of levodopa-induced dyskinesias on Health-related Quality of Life. Results from the French COPARK study.
Objective: To assess the impact of LIDs on HRQoL in this large sample of unselected Parkinson’s Disease (PD) patients and to assess the factors related…Protocol for upper-limb kinematic analysis in paediatric movement disorders and relative normality data
Objective: The study proposes a specialised protocol to collect and analyse kinematic data from paediatric patients affected by Movement Disorders (MD). The aim is to…Factors associated with occurrence of motor complications among Parkinson’s disease patients with levodopa treatment in Estonia
Objective: To identify the factors associated with the occurrence of motor complications among patients with Parkinson’s disease (PD) who receive levodopa treatment. Background: Levodopa is the…How efficient is subthalamic deep brain stimulation in reducing dyskinesia in Parkinson’s Disease?
Objective: The aim of this study was to determine whether the UDysRS can detect improvement in dyskinesia reliably after bilateral subthalamic nucleus DBS for PD.…Diphasic Dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion: diagnosis and management in clinical practice.
Objective: To describe the occurrence, diagnostic approach, clinical management and outcome of diphasic dyskinesias (Dyskinesias-Improvement-Dyskinesias, DID) in a large group of Parkinson’s Disaese (PD) patients…Antiphospholipid syndrome presenting with craniocervical dystonia: A case study
Objective: Antiphospholipid Syndrome (APLS) is a hypercoagulable state characterized by arterial or venous thrombosis and/or pregnancy morbidity with laboratory evidence of antiphospholipid antibodies. Movement disorders…Off-Target Implications of Nurr1 Agonist Therapy in Parkinson’s disease
Objective: To examine the impact of Nurr1 agonists on regulation of striatal Nurr1 and levodopa (LD)-induced dyskinesias (LIDs) in a rat model of Parkinson’s disease…Managing severe dyskinesia in Parkinson’s Disease using 24-hour Levodopa/Carbidopa Intestinal Gel Infusion
Objective: We report the effective treatment of troublesome dyskinesias in Parkinson’s disease (PD), unresponsive to 16-hour daytime infusions, using 24-hour Levodopa/Carbidopa Intestinal Gel (LCIG). Background:…Differential Item Functioning in the Unified Dyskinesia Rating Scale (UDysRS)
Objective: Test if differential item functioning (DIF) due to gender, age, race/ethnicity or education level is present in UDysRS items. Background: Testing a rating…
- « Previous Page
- 1
- …
- 34
- 35
- 36
- 37
- 38
- …
- 44
- Next Page »